AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comAUG 65 min read$BLFS

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates

BioLife Solutions, Inc. (BLFS) reported Q2 adjusted EPS of $0.04, versus a Zacks Consensus Estimate of a loss of $0.01. Revenue was $28.47 million, up from $25.42 million a year earlier and 1.48% above consensus. Ahead of the report, estimate revisions were favorable and the stock had a Zacks Rank #2 (Buy).

Original reporting
finance.yahoo.com
Published Aug 6, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BLFS
Bullish
medium confidence
Mentioned
$BLFS
Relevance
8/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$BLFSBullishMed
01

Why it matters

Traders can use the reported beats plus the stated current consensus outlook for the coming quarter and fiscal year to gauge whether expectations are likely to be raised or cut after the call.

02

Market read

This is a company-specific earnings catalyst with explicit beat figures and a stated near-term consensus baseline, making it actionable for short-term positioning.

03

What to watch

Follow-through risk is high if management commentary does not confirm revenue durability or if estimate revisions reverse after the call.

Relevance 8/10Novelty 7/10Timing: after-hours/next-session reaction to the just-released Q2 results and earnings call commentary

Background

The piece frames BioLife Solutions’ Q2 as an earnings and revenue beat versus consensus, then discusses how estimate revisions and the earnings call may drive the stock’s next move.

Company-level read

Ticker impact

$BLFSBullishMedium confidence
Context

BioLife Solutions reported Q2 EPS of $0.04 versus a consensus loss of $0.01 and revenues of $28.47M, beating estimates.

Expected impact

Likely positive near-term bias, with volatility tied to the earnings call and any changes to next-quarter and FY consensus.

Evidence & confidence

The text provides the surprise magnitude, current consensus outlook ($0.01 EPS next quarter, $0.03 FY), and notes favorable estimate revisions leading into the print.

Market effects

Sector

A beat in medical products can modestly support sentiment toward small-cap healthcare suppliers, but the article provides no broader sector signal beyond the company’s results.

Regional

No regional macro or cross-market linkage is provided.

Global

No international demand, regulatory, or supply-chain developments are mentioned.

Counterpoint

What could challenge this read

The article emphasizes adjusted, non-recurring items and a small absolute EPS level, so the “surprise” may not translate into durable earnings power.

Key entities

  • company
    BioLife Solutions, Inc.

    Reported Q2 EPS of $0.04 (vs consensus loss of $0.01) and revenues of $28.47M (vs consensus +1.48% beat).

  • estimate_source
    Zacks Consensus Estimate

    The benchmark used for EPS and revenue comparisons in the article.

  • rating_tool
    Zacks Rank

    The article cites a Zacks Rank #2 (Buy) based on favorable estimate revisions ahead of the release.

Read at source← All news

Related articles

SEP 4
$BLFSMedAI 8/10

[DEFM14A] BIOLIFE SOLUTIONS INC Merger Proxy Statement

BioLife Solutions (BLFS) filed a proxy statement for a merger with Repligen. The deal offers $11.25 and 0.1442 Repligen shares per BioLife share, pending stockholder approval on October 5, 2026. BioLife stock will be delisted if the merger completes. Repligen's share count will increase, diluting existing holders.

stocktitan.net2 min
SEP 4
$RGENHighAI 9/10

What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share

Repligen (RGEN) filed an amended Form S-4 to register shares for its acquisition of BioLife Solutions. The deal offers $11.25 in cash plus 0.1442 Repligen shares per BioLife share, pending approvals. The merger is subject to shareholder and regulatory approvals, with a special meeting scheduled for October 5, 2026. The exchange ratio is fixed, but the value of the share portion will fluctuate with Repligen's stock price.

stocktitan.net2 min
AUG 6
$BLFSHighAI 9/10

BIOLIFE SOLUTIONS INC (BLFS): Results of Operations and Financial Condition

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Results of Operations and Financial Condition. BioLife Solutions Reports Second Quarter 2026 Financial Results Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and n

SEC EDGAR 8-K6 min
AUG 6
$BLFSHighAI 9/10

BioLife Solutions Reports Second Quarter 2026 Financial Results

BioLife Solutions (Nasdaq: BLFS) reported Q2 2026 revenue of $28.5 million, up 21% year over year, with GAAP gross margin of 64% and non-GAAP gross margin of 65%. GAAP net income was $45.1 million, including a $42.4 million non-cash tax benefit; non-GAAP adjusted EBITDA was $7.4 million. BioLife said Repligen will acquire it for about $1.5 billion, expected to close in Q4 2026.

aol.com4 min
JUL 25
$BLFSMedAI 8/10

BioLife Solutions (BLFS) Faces Fairness Probes After Repligen Agrees To Buy It

Repligen agreed to acquire BioLife Solutions, a Nasdaq-listed cell therapy tools company. After the deal announcement, law firms opened investigations into whether the transaction is fair to BioLife shareholders, focusing on the sale process, conflicts, and valuation. The offer is $31.00 per share, about a 24% premium to 90-day VWAP, with 64% stock and 36% cash.

simplywall.st6 min